GLP-1 statistics: 65 numbers on usage, results and cost in 2026

Key takeaways

12% of US adults are currently taking a GLP-1, and 18% have taken one at some point.

GLP-1 prescribing per 100,000 US adults more than quadrupled between 2021 and 2026, from 1,884 to 8,819.

Tirzepatide beat semaglutide head to head, with 20.2% average weight loss against 13.7% over 72 weeks.

85% of people who start a GLP-1 for weight loss are no longer taking it two years later.

Mounjaro and Zepbound together made $27.7 billion in the first half of 2026.

Medicare’s negotiated semaglutide price is $274 a month from January 1, 2027, which is 71% below the previous list price.

Do you ever get the feeling that everyone is on Ozempic? According to our data, about one in eight US adults, or 12%, is currently taking a GLP-1 medication like Ozempic or Mounjaro¹. Prescribing has more than quadrupled in under five years³, and the two leading brands earned $27.7 billion in six months²⁸. Whatever corner of healthcare you work in, these drugs are reshaping it.

Below, you’ll find 65 GLP-1 statistics that not only tell the story of an industry, but of millions of people struggling with obesity and diabetes across the United States.

We’ll cover cover how many people take these drugs, their results, and how many people stop. Beyond that, we’ll also discuss what the medications cost and who pays, as well as the impact on the US med spa market.

A note on the facts: Every figure comes from a reputable and verified source. That means federal agencies, the survey houses that fielded the polls, peer-reviewed trials, and audited company results. The numbers are current as of August 2026.

65 GLP-1 statistics and facts at a glance

Every statistic below sits in one of 11 sections. Use the list to jump straight to the number you need, or read on for the full picture.

The history of GLP-1s: From lizard venom to household name

GLP-1s look like an overnight success, but the science behind them is nearly a century old. Researchers proposed in 1932 that the gut releases hormones that amplify insulin, and named them incretins⁴⁵. In 1964, two research teams proved it. Glucose taken by mouth triggered far more insulin than the same dose injected into a vein⁴⁵.

The hormone itself surfaced in the 1980s, when scientists decoding the proglucagon gene identified GLP-1⁴⁵. In 1987, Dr. Svetlana Mojsov had shown it stimulates insulin only when blood sugar is high⁴⁵. That glucose-dependence explains why the class causes so little hypoglycemia, and it made the hormone worth turning into a drug.

However, one obstacle stalled the field for years: the body destroys natural GLP-1 in under two minutes⁴⁵. The fix came from the desert. In 1992, Bronx-based researcher John Eng isolated exendin-4 from Gila monster venom, a natural GLP-1 mimic the body couldn’t break down⁴⁵. A synthetic version became Byetta, the first GLP-1 medicine, in 2005²⁴.

GLP1 technology has since evolved at a rapid pace Daily injections became weekly ones, then pills. The target widened from diabetes to obesity, then to the heart, kidneys, liver and even sleep apnea.

The timeline below draws its approval dates from FDA records, its discovery history from the scientists’ own peer-reviewed account, and its 2023 milestone from Science^24,45,46.

GLP-1 usage statistics

The top-line GLP-1 usage statistics come from three key sources, though each study follows a different methodology. The table below clarifies what each source measures, because the three headline figures answer different questions.

1. About one in eight US adults is currently taking a GLP-1

According to a KFF poll of 1,350 Americans, 12% of US adults currently take a GLP-1, and 18% have taken one at some point¹.

Importantly, there has been massive growth in the past two years. Current use is up six points from 6% just 18 months earlier¹. In plain terms, the number of users doubled in 18 months. Very few prescription categories in modern medicine have ever grown that fast.

2. GLP-1 use for weight loss reached 11% of US adults, and 15% have tried one

11% of US adults currently take a GLP-1 for weight loss, up from 3% two years earlier². Gallup surveyed 5,065 adults between May 28 and June 5, 2026, with a margin of error of plus or minus 1.5 points.

Ever-use for weight loss tells the same story. 15% of US adults have used a GLP-1 for weight loss at some point, up nine points in two years². Set that against the 11% still taking one, and 4% of adults have tried a GLP-1 and stopped. The discontinuation numbers later in the article explain why.

3. GLP-1 prescribing per 100,000 adults more than quadrupled since 2021

GLP-1 prescribing rose from 1,884 per 100,000 US adults in Q2 2021 to 8,819 in Q1 2026³. The figure comes from a health-records dataset holding more than 304 million patient records.

Keep in mind, though, that this is the prescription rate, not a patient count. However, even with that caveat, a quadrupling in under five years signals a change in prescribing culture, not just patient demand.

4. Tirzepatide overtook semaglutide as the most-prescribed GLP-1

Tirzepatide ran at roughly 4,700 prescriptions per 100,000 adults in Q1 2026, against about 3,900 for semaglutide³. By contrast, five years earlier, the leaders were dulaglutide at around 790 and semaglutide at around 680. Neither of today’s leaders was on the market five years ago. Prescribers clearly follow the efficacy data, and the head-to-head trial below shows what convinced them.

The brand names map like this. Tirzepatide is sold as Mounjaro and Zepbound, while semaglutide is sold as Ozempic, Wegovy, and Rybelsus.

5. 91% of US adults know about GLP-1 drugs, and 37% know someone taking one

91% of US adults are now aware of GLP-1 drugs for weight loss, up from 80% two years earlier². The category is mainstream, not emerging, and that awareness is part of why the prevalence figures keep moving.

At the same time, 37% of US adults say a close friend or family member uses a GLP-1¹, which is probably why you get that feeling that everyone is on Ozempic. Set that against the 12% who actually are, and the arithmetic explains the perception on its own.

How many Americans are on GLP-1, by age, diagnosis and eligibility

12% of American adults are currently on a GLP-1, which works out to roughly one in eight¹. The percentage of Americans on GLP-1s varies sharply by age, diagnosis, and insurance, so the sections below break the population apart.

Two data families run through this section, and they measure different things. KFF surveys all US adults. The CDC’s most recent data brief surveys only adults with diagnosed diabetes. Each figure below names which one it comes from.

6. GLP-1 use peaks in middle age, at 22% of adults aged 50 to 64

22% of adults aged 50 to 64 currently take a GLP-1¹. That compares with 11% at ages 30 to 49, 9% at 65 and over, and 4% at 18 to 29. This is the group most likely to have both a qualifying diagnosis and employer coverage, and the usage data reflects it.

The drop after 65 is the first hint of the Medicare coverage story. The cost section further down picks it up in full.

7. 26.5% of adults with diagnosed diabetes (about 6.9 million people) use an injectable GLP-1

More than one in four adults with diagnosed diabetes, 26.5%, used an injectable GLP-1 in the CDC’s most recent national survey⁴. That works out to about 6.9 million people. It is the only federal count in this article that converts a percentage into a headcount. Note it covers injectables only, which excludes the semaglutide pills.

By contrast, KFF’s survey asks a broader question and finds even higher rates. 45% of adults with a diabetes diagnosis take a GLP-1, alongside 29% of those with heart disease¹.

Within the diabetes population, injectable use runs 25.3% at ages 18 to 34 and peaks at 33.3% at 50 to 64⁴. It then drops to 20.8% at 65 and over. The fall at 65 lines up with the move onto Medicare, which did not cover obesity medicines at the time.

Use also varies by race and by weight. Among adults with diagnosed diabetes, injectable GLP-1 use was 31.3% in Hispanic adults and 26.5% in Black adults⁴. It was 26.2% in White adults and 12.1% in Asian adults. The source reports the spread without offering a cause. Use tracks BMI too, from 16.7% at a healthy weight to 32.4% with obesity⁴.

One more pattern matters for practices. 31.3% of diabetes patients on insulin also used an injectable GLP-1, as did 28.1% of those on oral glucose-lowering medication⁴. In practice these are combination therapies, not replacements.

8. 38% of GLP-1 users took it for a chronic condition, and 30% primarily for weight loss

Among US adults who have ever taken a GLP-1, 38% took it primarily for a chronic condition¹. Another 32% took it for both a condition and weight loss, and 30% primarily for weight loss. By the patients’ own account, the category is majority medical.

Meanwhile, 15% of people who have taken a GLP-1 have no diagnosis of diabetes, heart disease, or obesity¹. That is one user in seven. The survey does not ask why, so the figure stands on its own.

9. 42% of privately insured adults meet the criteria for a GLP-1, but fewer than one in 10 take one

42% of adults under 65 with private health insurance, 57.4 million people, meet the clinical criteria for a GLP-1⁵. The same analysis notes only about 3% of adults with employer coverage had a GLP-1 prescription when it was published⁵. There’s a surprising gulf between those number, but it would appear growth in this category is limited by price and coverage, not by appetite for the drugs.

The industry reads the shortfall the same way. Eli Lilly’s chief executive David A. Ricks put it plainly in April 2026: fewer than one in 10 people who could benefit are taking one⁶.

10. 22% of non-users want a GLP-1, rising to 43% among those told they are overweight

22% of adults not currently taking a GLP-1 are interested in one for weight loss¹. That rises to 43% among adults who have been told they are overweight or obese. It splits 27% of women against 18% of men. This bears out in our internal data as well, which shows women are more likely to seek GLP-1 treatments at med spas.

Average weight loss on GLP-1 medications

Average weight loss on GLP-1 medications ranges from about 12% to about 21% of body weight in the pivotal trials, depending on drug and dose. The table compares the trials side by side. Every figure is a trial result, which assumes supervised dose escalation and adherence. The persistence numbers in the next section show what happens without that.

11. Average weight loss on Wegovy was 14.9% over 68 weeks

Adults on semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks in STEP 1, against 2.4% on placebo⁷. The trial enrolled 1,961 adults with overweight or obesity and no diabetes. In absolute terms that was 15.3 kg against 2.6 kg. The trial was funded by Novo Nordisk, the drug’s maker.

This is the number most often quoted as average weight loss on Ozempic, but this is a misattribution The drug is semaglutide, and the brand approved for weight management is Wegovy.

The averages hide the spread, so the threshold figures matter. In STEP 1, 86.4% of semaglutide patients lost at least 5% of their body weight and 69.1% lost at least 10%⁷. Half, 50.5%, lost at least 15%. Placebo ran 31.5%, 12.0%, and 4.9%.

12. Average weight loss on Zepbound reached 20.9% over 72 weeks

Tirzepatide produced average weight loss of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks in SURMOUNT-1⁸. Placebo ran 3.1%.

The trial enrolled 2,539 adults with obesity and no diabetes, with a mean starting weight of 104.8 kg. It was funded by Eli Lilly, the drug’s maker. Tirzepatide is called Zepbound when used for weight management and Mounjaro for type 2 diabetes.

At the top dose, 91% of participants lost at least 5% of their body weight and 57% lost at least 20%⁸. Placebo ran 35% and 3%. Losing a fifth of body weight is the result that separates this class from everything before it.

13. Three years in, tirzepatide patients were still down 19.7%

At week 176 of SURMOUNT-1, participants still on tirzepatide 15 mg were down 19.7%, against 1.3% on placebo⁹. The lower doses held at 12.3% and 18.7%. This is the longest randomized weight-maintenance evidence in the class.

14. Head to head, tirzepatide beat semaglutide 20.2% to 13.7%

If you’re asking which GLP-1 is best for weight loss, the only direct comparison says tirzepatide. In SURMOUNT-5, tirzepatide 10 or 15 mg produced 20.2% mean weight loss over 72 weeks, against 13.7% for semaglutide 1.7 or 2.4 mg¹⁰. The trial enrolled 751 adults with obesity and no diabetes.

Waist circumference fell 18.4 cm against 13.0 cm¹⁰. The trial was open label, and it was funded by Eli Lilly, tirzepatide’s maker, which means there may be some bias in the interpretation of the numbers.

15. The Wegovy pill delivered 16.6% mean weight loss, and the 7.2 mg dose up to 20.7%

Oral semaglutide 25 mg, the Wegovy pill, delivered 16.6% mean weight loss in the OASIS 4 trial¹¹. It was approved on December 22, 2025. The 16.6% is the if-treatment-adhered estimand. Novo Nordisk describes the result as similar to the 2.4 mg injection. The release did not state the sample size or duration.

The higher 7.2 mg injectable dose, Wegovy HD, produced up to 20.7% mean weight loss in the STEP UP trial¹². “Up to” is the trial’s best-case estimand, not the typical result. This dose also carries a new safety signal, covered in the side effects section below.

16. Foundayo, the first small-molecule GLP-1 pill, produced 12.4% average weight loss

Adults on the highest dose of orforglipron, sold as Foundayo, lost an average of 27.3 lb, or 12.4%, if they stayed on treatment⁶. Across everyone randomized in the ATTAIN-1 trial, the loss was 11.1%, or 25 lb. Placebo ran 0.9% and 2.1% on the same two estimands. Any quote of this trial should say which estimand it means.

17. Retatrutide produced 28.3% average weight loss and CagriSema 22.7%. Neither is approved

Retatrutide is investigational and not approved anywhere, but its trial numbers explain the attention. The 12 mg dose produced 28.3% mean weight loss, or 70.3 lb, at 80 weeks in TRIUMPH-1¹⁴. That approaches a third of total body weight, a scale of loss no approved medication has ever produced.

45.3% of participants lost at least 30% of their body weight. In the blinded extension, participants starting at a BMI of 35 or more were down 30.3% at 104 weeks¹⁴. A US submission is planned for early 2027.

The same trial moved most participants out of the obesity range. 65.3% of those on retatrutide 12 mg fell below a BMI of 30 at 80 weeks, from a mean starting BMI of 40.0¹⁴. That included 37.5% of those who started with class 3 obesity. Again: this drug is investigational and cannot be prescribed.

CagriSema, also investigational in the US, produced 22.7% weight loss at 68 weeks against 2.3% on placebo in REDEFINE 1¹². More than 40% of its 3,417 participants lost a quarter of their body weight. In a separate head-to-head trial it came in at 15.2% against 15.8% for tirzepatide 15 mg, non-inferior on weight but not on blood sugar control¹².

How many people gain weight back after Ozempic and other GLP-1s

In the key withdrawal study, patients regained about two thirds of their lost weight within a year of stopping semaglutide¹⁵. Real-world data is more forgiving, and the disagreement between the two is the honest finding.

Two different questions hide inside this one. What happens to weight when treatment stops, and how many people stop at all. Randomized withdrawal trials answer the first. Pharmacy claims answer the second, by counting refills rather than outcomes. Each figure below says which kind it is.

18. A year after stopping semaglutide, patients had regained about two thirds of their loss

327 STEP 1 participants followed for a year off treatment regained 11.6 percentage points of the weight they had lost¹⁵. They ended 5.6% below their starting weight at week 120. The cardiometabolic improvements reversed alongside the weight. This single study sits behind almost every “people regain two thirds” claim in circulation.

The STEP 4 withdrawal trial shows the same fork in the road. After a 20-week run-in, 803 adults were randomized to continue semaglutide or switch to placebo for 48 weeks¹⁶. Continuing produced a further 7.9% loss. Switching produced a 6.9% regain. The two arms diverge by nearly 15 points from the same starting point.

19. In SURMOUNT-4, stopping tirzepatide brought back 14.0% while continuing removed another 5.5%

670 adults were randomized after a 36-week tirzepatide lead-in and followed to week 88¹⁷. Those who continued reached 25.3% total loss from the start. Those withdrawn to placebo regained 14.0% and landed at 9.9%. The regain is larger than in the semaglutide trials, consistent with the larger loss being maintained.

89.5% of people who stayed on tirzepatide kept at least 80% of their initial weight loss, against 16.6% of those switched to placebo¹⁷. That is the clearest maintenance figure in the class.

20. Two years after stopping, 56% of semaglutide patients had held onto their weight loss

A health-records analysis followed 188,722 patients who stopped a GLP-1 after at least 90 days on treatment¹⁸. Two years later, 56% of semaglutide patients, 55% of tirzepatide patients, and 52% of liraglutide patients had held their loss or lost more. This is the most optimistic real-world regain figure available. It covers patients who lost at least 5 lb on treatment.

The same dataset shows the other tail. Complete weight regain within two years occurred in 23% of semaglutide patients, 21% of tirzepatide patients, and 27% of liraglutide patients¹⁸. Weight trajectories stabilized after 12 months, so the one-year picture largely sets the two-year one.

This data disagrees in tone with the withdrawal trials above. Naming that disagreement is more useful than resolving it. Trials measure a forced, clean stop, whereas records capture people who taper, switch, or restart.

21. 85% of people who start a GLP-1 for weight loss stop within two years, and only 8% remain at three

Pharmacy claims research on commercially insured members without diabetes found only 15% still filling GLP-1 prescriptions at two years¹⁹. Wegovy had the highest two-year persistence at 24%, with Ozempic at 22%. Claims data measures refills collected, not outcomes.

At three years, the same research group found only 8% of people, one in 12, still on a GLP-1 for obesity²⁰. The cohort was 5,780 individuals without diabetes, mean age 47 and about 80% female.

Persistence rose to 14% for the high-potency products Wegovy and Zepbound. For a practice running a weight-loss program, this is the number to build around. Nearly every patient who starts will, at some point, need a reason to stay.

22. One-year persistence nearly doubled, from 33% of 2021 starters to 63% of 2024 starters

Across 23,025 individuals on high-potency GLP-1s, one-year persistence rose from 33% for 2021 starters to 63% for early-2024 starters²⁰. This is the counterweight to the 85% and 8% figures above, and leaving it out would make them misleading.

Staying on treatment is becoming the norm rather than the exception. Falling prices, wider employer coverage, and better side-effect management are the likeliest drivers, and all three are still improving.

23. 14% stopped because of cost and 13% because of side effects

Among US adults who stopped taking a GLP-1, 14% cited cost and 13% cited side effects¹. Only 5% stopped because their condition improved. Cost being the leading reason is what makes the pricing section below more than a list of numbers.

GLP-1 side effects by the numbers

The most common GLP-1 side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. Every rate below comes from the FDA-approved prescribing information or a peer-reviewed trial, and each sentence names which. The rates for different drugs come from separate trials with different populations, so they are shown side by side, not ranked. Anyone weighing these numbers should talk to their prescriber.

24. Nausea affects 44% of people on semaglutide 2.4 mg

44% of people on semaglutide 2.4 mg reported nausea, against 16% on placebo, in the pooled weight-management trials on the FDA label²¹. The pooled set covered 2,116 treated patients against 1,261 on placebo. The same data gives diarrhea at 30% against 16% and vomiting at 24% against 6%. Constipation ran 24% against 11%, and abdominal pain 20% against 10%.

25. 6.8% stopped semaglutide over side effects in 68 weeks, and 16.6% over nearly three years

6.8% of people on semaglutide 2.4 mg stopped treatment permanently because of side effects, against 3.2% on placebo, per the FDA label’s pooled trials²¹. The most common reasons were nausea at 1.8%, vomiting at 1.2%, and diarrhea at 0.7%. The 13% who told KFF they stopped over side effects is higher because trials support patients through dose escalation¹.

Longer exposure raises the number. In the SELECT trial, which followed 17,604 patients for a mean of 34 months, 16.6% discontinued permanently for adverse events against 8.2% on placebo²³. That is the best long-duration discontinuation figure in the class.

26. Gallstones were reported by 1.6% on semaglutide against 0.7% on placebo

Gallstones affected 1.6% of adults on semaglutide 2.4 mg against 0.7% on placebo, per the FDA label²¹. Gallbladder inflammation ran 0.6% against 0.2%. Rates were higher in adolescents, where gallstones occurred in 3.8% of treated patients and none on placebo.

27. On tirzepatide, nausea affected 25% to 29% and gastrointestinal side effects 56%

Nausea affected 25% of patients at 5 mg, 29% at 10 mg, and 28% at 15 mg of tirzepatide, against 8% on placebo²². The figures come from the pooled weight-reduction trials in the current Zepbound prescribing information, covering 2,519 adults.

Gastrointestinal side effects overall hit 56% of people on tirzepatide at every dose, against 30% on placebo²². Note that nearly a third of the placebo group also reported GI symptoms. The treatment-attributable share is therefore smaller than the raw 56% suggests. Discontinuation for adverse reactions ran 4.8% to 6.7% by dose, against 3.4% on placebo.

28. Every GLP-1 in this class carries a boxed warning for thyroid C-cell tumors

Every GLP-1 label carries a boxed warning for thyroid C-cell tumors, and the warning is based on rodent studies²¹. The drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.

The label publishes no human incidence rate, so no GLP-1 cancer percentage exists to quote. The warning, its basis, and the contraindication are where the evidence stops.

29. The FDA flagged altered skin sensation at the 7.2 mg semaglutide dose

On approving Wegovy HD in March 2026, the FDA identified skin sensitivity, pain, or burning as a common reaction at the 7.2 mg dose¹³. The agency said it is still investigating. The reaction generally resolved on its own or with a dose reduction. This is the newest safety signal in the class.

How many GLP-1 drugs are there, and what they are approved to treat

Ten branded GLP-1 medicines have been approved in the US, spanning seven molecules, plus two generics referencing the older drugs. The FDA has approved or expanded a GLP-1 medicine 21 times since 2005, counting new approvals, indication expansions, and generics together²⁴. The full record is below.

One row needs flagging. The generic semaglutide holds a tentative approval, which means it meets the standard but cannot be sold. It is not available to patients yet.

30. Mounjaro reached the market in 2022, Zepbound in 2023 and the first GLP-1 pill for weight loss in 2025

Mounjaro was approved on May 13, 2022, so it has been on the market just over four years as of August 2026²⁴. Zepbound followed on November 8, 2023, making it under three years old. Wegovy was approved on June 4, 2021, five years ago. The Wegovy pill arrived on December 22, 2025, and Foundayo, the first small-molecule oral GLP-1, on April 1, 2026.

The class is older than its fame. Byetta was the first US GLP-1 in April 2005, for type 2 diabetes, and Saxenda became the first approved for obesity in December 2014²⁴. Across those two decades the FDA has approved or expanded a GLP-1 medicine 21 times²⁴.

31. Semaglutide cut major cardiovascular events by 20% and kidney disease events by 24%

In the SELECT trial, 6.5% of patients on semaglutide had a major cardiovascular event against 8.0% on placebo, a 20% relative reduction²³. The trial followed 17,604 patients aged 45 and over with obesity and heart disease but no diabetes, for a mean of 39.8 months. This result earned Wegovy its cardiovascular indication in March 2024²⁶.

The kidneys followed. In the FLOW trial of 3,533 patients with type 2 diabetes and chronic kidney disease, semaglutide cut major kidney disease events by 24%²⁷. All-cause death fell 20%. The trial was stopped early because the benefit was already clear.

32. Tirzepatide cut progression to type 2 diabetes by 93%

In the SURMOUNT-1 prediabetes subgroup of 1,032 participants, 1.3% developed type 2 diabetes over 176 weeks, against 13.3% on placebo⁹. After 17 weeks off treatment the difference narrowed but held, at 2.4% against 13.7%. Twelve points of absolute difference over three years is the clearest prevention result in the class.

33. Semaglutide resolved steatohepatitis in 63% of MASH patients

63% of patients with MASH, a serious fatty liver disease, saw their steatohepatitis resolve without worsening fibrosis at 72 weeks, against 34% on placebo²¹. The trial covered 800 adults with moderate to advanced fibrosis. Fibrosis improved without worsening steatohepatitis in 37% against 22%. The indication was granted accelerated approval in August 2025, so confirmatory data is still pending.

The same trial produced 10.5% average weight loss against 2% on placebo²¹. Weight was a secondary endpoint here. The indication rests on liver histology.

34. Zepbound became the first drug ever approved for obstructive sleep apnea

Zepbound was approved for moderate to severe obstructive sleep apnea on December 20, 2024, the first drug treatment for the condition of any kind²⁵. The approval rested on two 52-week trials in 469 adults with sleep apnea and obesity. Measured on the apnea-hypopnea index, more patients reached remission or mild disease than on placebo.

GLP-1 market size, sales and market share

The GLP-1 market’s two makers reported tens of billions of dollars in obesity and diabetes medicine sales in the first half of 2026 alone. Every figure in this section is audited and dated.

All of them come from Eli Lilly’s Q2 results of August 5, 2026, or Novo Nordisk’s half-year report of August 4, 2026. One rule holds throughout. Novo reports in Danish kroner and Lilly in US dollars, so the two are never added together here.

35. Lilly’s two tirzepatide brands made $27.7 billion in six months

Mounjaro’s $18,605 million plus Zepbound’s $9,088 million comes to $27,693 million for the first half of 2026²⁸. That sum, added here from the two reported product lines, is more than the company’s entire 2022 revenue.

The quarterly detail is just as striking. Mounjaro alone brought in $9.94 billion in Q2 2026, up 91% year on year²⁸. That works out to about $109 million in sales every single day of the quarter. Revenue outside the US rose 172%, helped by China adding tirzepatide to its reimbursement list. Zepbound reached $4.93 billion, up 46%²⁸.

Tirzepatide drove Lilly’s total revenue up 48% to $23.0 billion in the quarter²⁸. Volume rose 60% while realized prices fell 13%, the clearest illustration of the price-for-volume trade running through this market. Foundayo added $98 million in its first partial quarter, a useful scale check against the billions above²⁸.

36. Novo Nordisk’s obesity division sold DKK 44.1 billion of medicine in six months

Novo Nordisk’s obesity care division sold DKK 44,064 million of medicine in the first half of 2026, up 19% at constant exchange rates¹². The figure is reported in Danish kroner, so it is left in kroner here.

Wegovy injectable generated DKK 37.7 billion of that, and the Wegovy pill DKK 5.5 billion¹². The pill launched on January 5, 2026, so its number covers a partial half-year. Meanwhile Saxenda, the first GLP-1 ever approved for weight management, collapsed 54% to DKK 871 million¹². This class replaces its own older products fast.

37. Ozempic remains Novo’s largest product at DKK 59.2 billion

Ozempic revenue reached DKK 59,200 million in the first half of 2026, with the oral semaglutide products adding DKK 9,800 million¹². Ozempic sales fell 2% at constant exchange rates as US prices came down. A falling revenue number here does not mean falling volume.

38. GLP-1 market share by company: Novo holds 81% of branded obesity volume

Novo Nordisk holds 81% of the global branded obesity market by volume, on May 2026 market data cited in its own report¹². Its US share is 87% and its international share 71%. One caveat matters here. This is volume share, not value. Also, in most non-US markets tirzepatide is classified under diabetes, which flatters the obesity share.

For patient reach rather than market share, Novo says its medicines treated 4.9 million people with obesity in the first half of 2026¹². Another 41.6 million of its patients were living with diabetes. That is one company’s own patient count, not the size of the market. No organization publishes a global patient total for the class.

39. The Wegovy pill passed five million US prescriptions, and Wegovy runs at 575,000 a week

The Wegovy pill passed five million US prescriptions between its January 5, 2026 launch and mid-July, with about 2.9 million in Q2 alone¹². Novo calls it the strongest GLP-1 volume launch the US has seen, a claim that belongs to Novo rather than to neutral data.

Total weekly Wegovy prescriptions ran at about 575,000 in mid-July 2026, split roughly 310,000 injectable and 265,000 pill¹². About 120,000 of the injectable scripts were self-pay, which connects this figure to the pricing section below.

40. GLP-1 usage by country: Wegovy is now launched in around 60 markets

Wegovy is launched in around 60 countries as of mid-2026¹². No organization publishes a country-by-country GLP-1 patient count, so launch footprint is the closest verifiable proxy. Pair it with the 71% international volume share above, remembering that tirzepatide sits under diabetes in most non-US markets.

The average cost of GLP-1 without insurance

The average cost of a GLP-1 without insurance now runs from $149 to $499 a month through the manufacturers’ direct channels. List prices used to top $1,000. US GLP-1 prices moved repeatedly across 2025 and 2026, and several changes are dated into the future. Every price below carries its effective date, because a GLP-1 price without a date is meaningless.

41. Wegovy listed at $1,350 a month and Ozempic at $1,000 before November 2025

Wegovy’s US list price stood at $1,350 a month, Ozempic’s at $1,000, and Zepbound’s at $1,086, as of November 2025²⁹. These are the federal government’s stated benchmarks, and every later cut is measured against them. They are list prices, which almost nobody paid in full.

42. Ozempic and Wegovy fell to $350 a month through TrumpRx

Under the November 2025 most-favored-nation agreement, Ozempic went from $1,000 to $350 a month and Wegovy from $1,350 to $350 in the direct-to-consumer channel²⁹. Zepbound and orforglipron went from $1,086 to an average of $346.

For Wegovy, that is a 74% cut, effectively overnight. Oral GLP-1s start at $150 a month at the starting dose. This is the single largest price movement in the class’s history.

43. Zepbound single-dose vials run $299 to $449 through LillyDirect

The average cost of Zepbound without insurance is $299 to $449 a month in vial form, from December 1, 2025³⁰. Inside the Self Pay Journey Program, the 2.5 mg dose is $299, the 5 mg is $399, and all other doses are $449.

Outside the program, a refill past the 45-day window runs $599 for 7.5 mg up to $1,049 for 15 mg³⁰. The difference between the two schedules is the whole incentive to stay enrolled.

44. The GLP-1 pills self-pay from $149 a month

The Wegovy pill self-pays at $149 to $299 a month by dose, through retail and the maker’s own pharmacy¹². Set that against the five million prescriptions in six months from the market section. The price and the volume explain each other.

Foundayo shows how many prices one product can have. It starts at $149 a month self-pay at the lowest dose⁶. Commercially insured patients pay as little as $25 with the savings card. Eligible Medicare patients pay $50 a month from July 1, 2026. That is three prices for the same pill.

45. Medicare’s negotiated semaglutide price is $274 a month from January 2027

Medicare’s negotiated price for semaglutide will be $274 for a 30-day supply from January 1, 2027, 71% below the earlier $959 list benchmark³¹. The maximum fair price applies across Ozempic, Rybelsus, and Wegovy. It takes effect next year and is not in force as this article publishes.

The list price is falling too. Novo Nordisk will cut the US list price of Wegovy, Ozempic, and Rybelsus to $675 a month from January 1, 2027³². That is roughly a 50% cut for Wegovy and 35% for Ozempic. It helps people whose out-of-pocket cost is tied to list price, such as high-deductible plans, and leaves self-pay prices unchanged.

46. The same product now has four different prices depending on who is paying

Semaglutide as of August 2026 carries four different prices at once:

• A list price of $1,350, falling to $675 in 2027^29,32
• A direct-to-consumer self-pay price of $350²⁹
• A negotiated Medicare price of $274 from January 2027³¹
• A $50 beneficiary copay under the Medicare demonstration³³

None of them is “the price” of the drug. A quoted figure means nothing without its channel and its effective date.

GLP-1 insurance coverage statistics

GLP-1 insurance coverage is widest through large employers and Medicare, and thinnest through state Medicaid programs. This section runs from private coverage through what patients actually pay, then to the public programs whose spending numbers are the largest in this article.

47. 43% of the largest US employers now cover GLP-1s for weight loss

43% of US firms with 5,000 or more workers now cover GLP-1s for weight loss, up from 28% a year earlier³⁴. Coverage falls to 30% at firms with 1,000 to 4,999 workers and 16% at 200 to 999. Company size is the strongest predictor of whether a GLP-1 is covered.

Coverage existing and coverage being reachable are different things. 34% of covering employers require employees to see a dietitian, case manager, or therapist, or join a lifestyle program, before they qualify³⁴.

The demand also caught employers off guard. 59% of the largest covering firms say use ran higher than they expected³⁴. Next to the 57.4 million eligible privately insured adults, that surprise was arithmetic waiting to happen.

48. 70% of GLP-1 users had some coverage, but 56% still find it difficult to afford

70% of GLP-1 users had insurance that covered at least part of the cost, and 22% had it covered in full¹. Yet 27% had insurance and still paid the full price themselves. Having coverage and having the drug covered are not the same thing.

56% of people taking a GLP-1 say it is difficult to afford, and a quarter say it is very difficult¹. That includes 55% of insured users. Affordability is the mechanism behind the persistence figures earlier in this article, where cost was the leading reason for stopping.

49. Gross Medicare Part D spending on GLP-1s hit $27.5 billion, a five-fold rise since 2019

Gross Medicare Part D spending on GLP-1s reached $27.5 billion in the most recent full year of data, five times its 2019 level³⁵. Analysts estimate net spending at around $14 billion assuming 50% rebates, so the gross figure is not cash out the door.

Ozempic accounted for 47% of that gross spending and Mounjaro 23%. A program built around far cheaper chronic medicines is now absorbing a $1,000-a-month class at scale. That pressure is exactly what produced the negotiated 2027 price covered earlier.

Semaglutide alone cost the program $15.2 billion gross across its three brands, covering 2,282,000 enrollees³¹. That is more than any other drug selected for Medicare price negotiation. On the volume side, Part D GLP-1 claims rose from 4.8 million to 21.8 million over five years³⁵. Those are claims rather than patients, since one patient on year-round treatment generates many.

50. Ozempic users in Medicare Part D grew from under 150,000 to 2 million

Ozempic went from fewer than 150,000 Medicare Part D enrollees to 2 million over five years of program data³⁵. Mounjaro went from 54,000 to nearly 1 million in two. These are Medicare enrollees, not a national total. No organization publishes a total US patient count by brand.

51. Medicaid GLP-1 prescriptions rose sevenfold and spending went from $1 billion to almost $9 billion

Medicaid GLP-1 prescriptions rose sevenfold over five years, from about one million to more than eight million³⁶. Gross spending went from about $1 billion to almost $9 billion over the same period³⁶. GLP-1s moved from 1% of all Medicaid drug spending to more than 8%. That works out at roughly $1,000 per prescription before rebates.

52. Only 13 state Medicaid programs covered GLP-1s for obesity in January 2026

Only 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026³⁶. Four states dropped coverage in the preceding four months: California, New Hampshire, Pennsylvania, and South Carolina. Coverage is moving in both directions at once, not along a single trend.

53. Medicare’s GLP-1 Bridge gives eligible beneficiaries GLP-1s for $50 a month

The Medicare GLP-1 Bridge gives eligible Part D beneficiaries GLP-1s for $50 a month, from July 1, 2026 to December 31, 2027³³. It is a time-limited demonstration, not permanent coverage. The November 2025 agreement that set Medicare’s underlying price at $245 with a $50 copay is what made covering obesity medicines viable at all²⁹.

Where patients get GLP-1s: Doctors, GLP-1 telehealth and med spas

Most GLP-1 patients get their prescription from a doctor, but online providers and med spas hold a measurable share. This section covers the channels, the compounded market, the shortage that created it, and the state of generics.

54. 76% got their GLP-1 from a doctor, 17% online and 9% from a med spa

Among US adults who have ever taken a GLP-1, 76% got it from a primary care doctor or specialist¹. Another 17% used an online provider, and 9% a medical spa or aesthetic center. Respondents could pick more than one channel, so the figures don’t sum to 100. This is the only nationally representative measure of the med spa share of GLP-1 supply.

55. 19% of people using a GLP-1 for weight loss are on a compounded version

68% of weight-loss GLP-1 users are on a brand-name product, 19% on a compounded version, and 12% don’t know which they have². Compounded use persists well after the shortage exemption that allowed it ended, which the next section explains.

Compounded users are no less satisfied. 77% call their medication effective or extremely effective, against 74% of brand-name users². That is self-reported perception, not a measured outcome comparison. Cost drives the traffic: 66% of people who switched to a compounded version cited cost or insurance².

56. Semaglutide spent almost three years on the FDA shortage list

Semaglutide injection sat on the FDA’s shortage list from early 2022 until the shortage was declared resolved on February 21, 2025³⁷. Wegovy was listed from March 2022 and Ozempic from August 2022. Ending the shortage ended the legal basis for compounding copies, which is why the compounding figures above matter.

The tirzepatide shortage resolved two months earlier, on December 19, 2024, covering all six Mounjaro and all six Zepbound strengths³⁸.

57. The first generic GLP-1s arrived in late 2024

The first generic GLP-1s were approved in late 2024: a generic exenatide referencing Byetta in November, and a generic liraglutide referencing Victoza on December 23³⁹. Both reference older GLP-1s. No generic semaglutide or tirzepatide is marketed in the US.

A generic semaglutide exists on paper but cannot be sold. Apotex received tentative FDA approval on April 7, 2026 for three strengths²⁴. Tentative approval means the product meets the standard but cannot be marketed, usually for patent or exclusivity reasons. It should never be described as available.

58. There are more than 11,000 medical spas in the US, in a $17 billion industry

The US medical aesthetics industry has passed $17 billion, on the American Med Spa Association‘s own survey⁴⁰. It is growing by more than $1 billion a year. The underlying survey data sits behind a paid report, so these are the association’s published headline figures.

The association’s most recent openly published report counts more than 11,000 medical spas employing over 100,000 people⁴¹. Close to 90% of their patients are women, and nearly 70% of med spa owners are women. Those figures come from a survey fielded from late 2023 to early 2024, so they trail the market they describe.

Obesity statistics in the US behind GLP-1 demand

40.3% of US adults have obesity, and around 70% have obesity or overweight⁴². Every GLP-1 percentage above is a share of this population. Meanwhile, three independent readings now show US obesity flat or falling, agreeing on direction while measuring differently.

59. 40.3% of US adults have obesity, and around 70% have obesity or overweight

40.3% of US adults aged 20 and over have obesity, and another 31.7% are overweight, in the CDC’s most recent measured survey cycle⁴². These figures are measured, not self-reported. Men run 39.2% and women 41.3%.

The FDA frames the combined population as around 70% of American adults with obesity or overweight²⁶. That matches the measured split of 40.3% plus 31.7%, rounded. The two ways of saying it are the same number, not a contradiction.

60. Adult obesity has stopped rising, but severe obesity has not

Overall adult obesity has been flat across the past decade of CDC measurement, while severe obesity rose from 7.7% to 9.7%⁴². Two different trends sit inside one population. The second one is the population the highest-efficacy products are aimed at.

61. 21.1% of US children and teenagers have obesity

21.1% of US children and teenagers aged 2 to 19 have obesity, including 7% with severe obesity, with another 15.1% overweight⁴³. The figures come from the same measured CDC cycle as the adult data. They connect to the adolescent approvals earlier in this article: Wegovy has been cleared for patients aged 12 and over since late 2022²⁴.

62. Two independent datasets show US obesity falling, from 39.9% to 36.4% and from 42.3% to 40.7%

Gallup’s self-reported obesity rate fell from a record 39.9% in 2022 to 36.4% in 2026, across 10,091 adults². Self-reported rates run below the CDC’s measured figure. Gallup describes the correlation with GLP-1 use as inverse and stops short of claiming causation.

Health records point the same way. The obese share of US adults in one 304-million-record dataset slipped from 42.3% in Q2 2021 to 40.7% in Q1 2026³. The healthy-weight share rose from 25.1% to 25.6%.

That is a third independent read on the same direction of travel. For decades the national obesity line moved in only one direction. Three separate readings agreeing on even a modest decline is a milestone.

63. One in eight people worldwide lives with obesity

890 million adults worldwide live with obesity, 16% of the adult population, and another 2.5 billion are overweight, per the WHO’s latest fact sheet⁴⁴. Adult overweight rose from 25% in 1990 to 43% in the most recent data, and obesity more than doubled over the same period.

The children’s figures are starker. 160 million children and adolescents aged 5 to 19 were living with obesity in the latest global data, four times the 1990 rate⁴⁴. A further 35 million children under 5 were overweight.

64. High BMI was linked to 3.7 million deaths in one year

High BMI was linked to 3.7 million deaths from non-communicable diseases globally in the WHO’s most recent mortality data⁴⁴. The WHO reports it as an association rather than a proven cause.

65. More than 38 million Americans have diabetes, and 90% to 95% have type 2

More than 38 million Americans have diabetes, and 90% to 95% of them have type 2, per CDC figures cited by the FDA³⁹. This is the population the whole class was originally built for, and the one the prevalence section opened on.

GLP1 trends: Where they’re heading next

Three trends run through this record, and all three are accelerating. The first is the move to pills. Two oral GLP-1s reached the US market within four months of each other across late 2025 and early 2026²⁴. Pills need no needles and no cold storage, which removes two of the biggest barriers to mass adoption.

The second is raw efficacy. Retatrutide posted 28.3% average weight loss in trials, and CagriSema 22.7%. Neither is approved yet^12,14. Results in that range used to require bariatric surgery.

The third is price. One November 2025 agreement took the class from a $1,350 list price to $350 self-pay²⁹. A $274 negotiated Medicare price follows in 2027³¹. Each wave of this market arrives bigger and cheaper than the last, which looks more like a technology curve than a typical drug launch.

Put the three together and the direction is hard to miss. GLP-1s are moving from scarce, expensive specialty products toward everyday chronic medication. The open question is whether patients stay on them long enough to collect the benefit, and the numbers below tackle exactly that.

Track GLP-1 patient retention in your medical spa software

The single largest number in this dataset is a retention number, not a weight-loss number. 85% of people who start a GLP-1 for weight loss have stopped within two years, and only 8% remain at three^19,20.

Yet one-year persistence nearly doubled between 2021 and 2024 starters²⁰. Follow-up is the variable that moved. That makes retention a practice operations problem, and it is the one number in this dataset a practice can influence.

Practice management software like Pabau turns that follow-up into a system instead of a memory test. Automated recalls contact a patient who is due a check-in before the prescription lapses. 14% of patients stop over cost and 13% over side effects¹. Packages and payment plans catch the first reason, and scheduled check-ins catch the second.

The withdrawal trials showed weight returning when treatment stops, so maintenance deserves a record of its own. Progress tracking and before-and-after photos sit inside each patient’s file, making maintenance a documented phase rather than an assumption. Digital forms handle the intake, medical history, and consent paperwork a weight-loss program needs. Patients complete them before the appointment, and everything files straight to the record.

The med spa channel is measurable, too. 9% of GLP-1 users got their medication from a med spa or aesthetic center¹. The industry behind that channel tops $17 billion across more than 11,000 US practices⁴⁰. A practice running a structured GLP-1 program, rather than issuing a prescription, is working the one lever the persistence data says matters. Esteem Life Medical Group built its practice on digital records from day one, and keeps them in Pabau.

Keep your GLP-1 patients on track

Pabau's automated recalls, progress tracking and digital forms give your GLP-1 program the structured follow-up the persistence data rewards, so patients stay engaged.

Book a demo

Conclusion

The figures that get quoted about this class are trial figures. The figures that decide whether a patient benefits are persistence figures. They come from different studies, measure different things, and disagree.

A trial result answers what the drug can do under supervised escalation and steady follow-up. A persistence rate answers what happens in ordinary life, where cost, side effects, and lapsed appointments do their work. Use the first to judge the medicine and the second to judge the program around it. The programs are where the numbers are still moving.

For practices offering GLP-1 programs, the follow-up layer is the part you own. Book a demo to see how Pabau helps your practice keep GLP-1 patients engaged from first consult to maintenance.

Continue your research

Want to keep more of the patients you already have? 7 patient retention strategies that keep your clinic full turns the follow-up problem in this data into a practical playbook.

Running a weight-loss program? Best EMR for weight loss clinics compares the platforms built for exactly this patient journey.

Comparing platforms for your practice? Top 7 weight loss clinic software ranks the systems US practices use to run these programs.

Thinking about entering the market yourself? How to start a med spa walks through licensing, staffing and setup step by step.

Wondering where the revenue comes from? How weight loss clinics make money breaks down the income streams behind a GLP-1 program.

Frequently asked questions

Sources

1. KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use. Fielded October 27 to November 2, 2025.
2. Gallup. In U.S., GLP-1 Usage Reaches New High. Fielded May 28 to June 5, 2026.
3. Epic Research. GLP-1 Use Has More Than Quadrupled Since 2021 as Obesity Rates Continue to Show Signs of Decline. Data to Q1 2026.
4. CDC, National Center for Health Statistics. Data Brief No. 537: GLP-1 Injectable Use Among Adults With Diagnosed Diabetes.
5. KFF. How Many Adults with Private Health Insurance Could Use GLP-1 Drugs.
6. Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron). Press release, April 1, 2026.
7. Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.
8. Jastreboff et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.
9. Jastreboff et al. Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1, three-year results). New England Journal of Medicine, 2025.
10. Aronne et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine, 2025.
11. Novo Nordisk. FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults. Press release, December 22, 2025.
12. Novo Nordisk. Financial report for the period January 1, 2026 to June 30, 2026. Company announcement No 48/2026, August 4, 2026.
13. US Food and Drug Administration. FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide. Press announcement, March 19, 2026.
14. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Press release, May 21, 2026.
15. Wilding et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes, Obesity and Metabolism.
16. Rubino et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA.
17. Aronne et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA.
18. Epic Research. Two Years After Stopping GLP-1s, Most Patients Sustain at Least Some Weight Loss.
19. Prime Therapeutics. 1 in 7 stays on GLP-1 drugs for weight loss after two years.
20. Prime Therapeutics. Only 1 in 12 remain on a GLP-1 drug for obesity at three years. June 25, 2025.
21. US Food and Drug Administration. WEGOVY (semaglutide) injection, full prescribing information. 2025 revision.
22. US Food and Drug Administration. ZEPBOUND (tirzepatide) injection, full prescribing information. Current label via openFDA.
23. Lincoff et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.
24. US Food and Drug Administration. Drugs@FDA approval records, retrieved via the openFDA API. Data updated August 5, 2026.
25. US Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. Press announcement, December 20, 2024.
26. US Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. Press announcement, March 2024.
27. Perkovic et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.
28. Eli Lilly and Company. Lilly reports second-quarter 2026 financial results, raises full-year guidance. August 5, 2026.
29. The White House. Fact sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients. November 2025.
30. Eli Lilly and Company. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials. Press release, December 1, 2025.
31. Centers for Medicare and Medicaid Services. Fact sheet: Negotiated Prices for Initial Price Applicability Year 2027.
32. Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus. Press release, February 24, 2026.
33. Centers for Medicare and Medicaid Services. Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries. Press release, May 6, 2026.
34. KFF. 2025 Employer Health Benefits Survey.
35. KFF. Recent Trends in GLP-1 Use and Spending in Medicare. January 30, 2026.
36. KFF. Medicaid Coverage of and Spending on GLP-1s. January 16, 2026.
37. US Food and Drug Administration. Declaratory Order: Resolution of Shortages of Semaglutide Injection Products. February 21, 2025.
38. US Food and Drug Administration. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products. December 19, 2024.
39. US Food and Drug Administration. FDA Approves First Generic of Once-Daily GLP-1 Injection. Press announcement, December 23, 2024.
40. American Med Spa Association. Medical Spa State of the Industry statistics.
41. American Med Spa Association. 2024 Medical Spa State of the Industry Report.
42. CDC, National Center for Health Statistics. Health E-Stat 111: Prevalence of Overweight, Obesity, and Severe Obesity Among Adults Age 20 and Older.
43. CDC, National Center for Health Statistics. Health E-Stat 112: Prevalence of Overweight, Obesity, and Severe Obesity Among Children and Adolescents.
44. World Health Organization. Obesity and overweight fact sheet. Updated December 8, 2025.
45. Drucker, Habener, and Holst. Discovery, characterization, and clinical development of the glucagon-like peptides. Journal of Clinical Investigation, 2017.
46. Science. 2023 Breakthrough of the Year: Obesity meets its match. December 2023.